View Older Stories View More Recent Stories

Mar 27, 2023 05:02PM Monopar Therapeutics (MNPR) Phase 2b/3 VOICE Trial of Validive Did Not Meet the Pre-Defined Threshold for Efficacy
Mar 27, 2023 05:00PM Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
Mar 27, 2023 05:00PM Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
Mar 23, 2023 07:00AM Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
Mar 23, 2023 07:00AM Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
Mar 7, 2023 07:00AM Monopar to Present at the 35th Annual Roth Conference
Mar 7, 2023 07:00AM Monopar to Present at the 35th Annual Roth Conference
Feb 14, 2023 07:00AM Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
Feb 14, 2023 07:00AM Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
Jan 26, 2023 07:00AM Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
Jan 26, 2023 07:00AM Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
Jan 18, 2023 07:00AM Monopar Therapeutics (MNPR) Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort
Jan 18, 2023 07:00AM Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
Jan 18, 2023 07:00AM Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
Dec 12, 2022 07:09AM Monopar Therapeutics (MNPR) Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
Dec 12, 2022 07:00AM Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
Dec 12, 2022 07:00AM Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
Nov 16, 2022 07:01AM Monopar Therapeutics (MNPR) Reports Strong Clinical Data from Ongoing Camsirubicin Phase 1b Trial
Nov 16, 2022 07:00AM Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
Nov 16, 2022 07:00AM Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
Nov 10, 2022 08:00AM Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
Nov 10, 2022 08:00AM Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments
Oct 27, 2022 08:00AM Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
Oct 27, 2022 08:00AM Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
Oct 19, 2022 08:00AM Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
Oct 19, 2022 08:00AM Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
Oct 12, 2022 08:00AM Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
Oct 12, 2022 08:00AM Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting
Oct 5, 2022 08:00AM Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
Oct 5, 2022 08:00AM Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
Sep 28, 2022 08:00AM Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
Sep 28, 2022 08:00AM Monopar to Present at Roth Inaugural Healthcare Opportunities Conference
Aug 11, 2022 08:05AM Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Aug 11, 2022 08:05AM Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Mar 24, 2022 08:00AM Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
Mar 24, 2022 08:00AM Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments
Mar 8, 2022 08:00AM Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
Mar 8, 2022 08:00AM Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference
Feb 15, 2022 08:05AM Monopar Therapeutics (MNPR) Issues Update on Clinical and Preclinical Programs
Feb 15, 2022 08:05AM Monopar Announces Clinical and Preclinical Program Updates
Feb 15, 2022 08:05AM Monopar Announces Clinical and Preclinical Program Updates
Jan 7, 2022 07:05AM Monopar to Present at the H.C. Wainwright BioConnect Conference
Jan 7, 2022 07:05AM Monopar to Present at the H.C. Wainwright BioConnect Conference
Dec 8, 2021 08:07AM Monopar Therapeutics (MNPR) Advances Dosing of Camsirubicin to Highest Levels
Dec 8, 2021 08:00AM Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial
Dec 8, 2021 08:00AM Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial
Nov 12, 2021 08:00AM Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments
Nov 12, 2021 08:00AM Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments
Oct 27, 2021 08:05AM Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
Oct 27, 2021 08:05AM Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
View More Recent Stories View Older Stories